Ladenburg Thalmann Reiterates Buy Rating, $7.75 PT for CryoLife

In a company update published earlier today, Ladenburg Thalmann Financial Services reiterated its Buy rating and $7.75 price target for CryoLife, Inc. (NYSE: CRY).

Ladenburg Thalmann said in its report “CryoLife expects 2012 revenue from HeRO sales to be between $2.5MM and $3.5MM. The transaction is expected to be $0.09-$0.10 dilutive to earnings in FY-2012, which includes non-recurring transaction and integration charges of between $0.06-$0.08, of which $0.04-$0.05 is expected during Q2-2012. We would also anticipate slightly higher R&D expense related to HeRO, as the device is currently being modified and enhanced through prototyping.”

CryoLife, Inc. closed yesterday at $4.93.